Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1147-1152

  Yu, Yan ^a   Luk, Frederick ^a   Yang, Jia Lin ^a   Walsh, William R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

IGF 1R; Lung metastasis; Orthotopic mouse model of osteosarcoma; Phosphorylated MEK; Ras Raf MEK ERK pathway

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LEIOMYOSARCOMA; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TIBIA;

ANIMALS; BONE NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSTEOSARCOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); RAF KINASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 79956122399     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 32: 423-436, 2006. (Pubitemid 44309249)
2. Ferrari S and Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346, 2007. (Pubitemid 46883523)
3. Ritter J and Bielack SS: Osteosarcoma. Ann Oncol 21(Suppl 7): vii320-vii325, 2010.
4. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C and van der Graaf WT: The insulin-like growth factor system and sarcomas. J Pathol 217: 469-482, 2009.
5. Burrow S, Andrulis IL, Pollak M and Bell RS: Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69: 21-27, 1998. (Pubitemid 28452269)
6. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, Lollini PL, Picci P and Scotlandi K: Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 80: 581-588, 1999. (Pubitemid 29047524)
7. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA and Smith MA: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1190-1197, 2008. (Pubitemid 351555543)
8. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F and Picci P: Antitumour activity of the insulin-like growth factor-1 receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumours. Cancer Res 65: 3868-3876, 2005.
9. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J et al: Ras pathway activation in hepatocellular carcinoma and anti-tumoural effect of combined sorafenib and rapamycin in vivo. J Hepatol 51: 725-733, 2009.
10. Marampon F, Bossi G, Ciccarelli C, Di Rocco A, Sacchi A, Pestell RG and Zani BM: MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 8: 543-551, 2009.
11. Dass CR, Ek ETH and Choong PF: Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol 133: 193-198, 2007. (Pubitemid 46144095)
12. Cirone M, Di Renzo L, Trivedi P, Lucania G, Borgia G, Frati L and Faggioni A: Dendritic cell differentiation blocked by primary effusion lymphoma-released factors is partially restored by inhibition of P38 MAPK. Int J Immunopathol Pharmacol 23: 1079-1086, 2010.
13. Song L, Xiong H, Li M, Liao WT, Wang L and Wu J: Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-{kappa}B pathway in human non-small cell lung cancer. Clin Cancer Res 17(7): 1839-1849, 2011.
14. Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I, Miyazono K and Saitoh M: TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J 30: 783-795, 2011.
15. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y and Sznol M: PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23: 190-200, 2010.
16. Nakabayashi H and Shimizu K: HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/ extracellular signal-regulated kinase (MEK/ERK) signal pathways. Cancer Sci 102: 393-399, 2011.
17. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR and McCormick F: Ras signalling and therapies. Adv Cancer Res 102: 1-17, 2009.
18. Kolb EA and Gorlick R: Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 11: 307-313, 2009.
19. Wellbrock C, Karasarides M and Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875-885, 2004. (Pubitemid 39486539)
20. Boldt S and Kolch W: Targeting MAPK signalling: Prometheus' fire or Pandora's box? Curr Pharm 10: 1885-1905, 2004.
21. Sivaraman VS, Wang H, Nuovo GJ and Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483, 1997. (Pubitemid 27163797)
22. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J and Baselga J: Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: 6500-6510, 2001. (Pubitemid 32783257)
23. Saidak Z, Boudot C, Abdoune R, Petit L, Brazier M, Mentaverri R and Kamel S: Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor. Exp Cell Res 315: 2072-2080, 2009.
24. Menakongka A and Suthiphongchai T: Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol 16: 713-722, 2010.
25. Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO and Der CJ: KRASIBRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8: 834-843, 2009.
26. Ohwada A, Hirschowitz EA and Crystal RG: Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 7: 1567-1576, 1996. (Pubitemid 26302211)
27. Kim J, Yu W, Kovalski K and Ossowski L: Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94: 353-362, 1996. (Pubitemid 28376079)
28. Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND and Quigley JP: A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res 62: 7083-7092, 2002. (Pubitemid 35424104)